Bluebird’s Beta-Thalassemia Gene Therapy Faces US Panel Scrutiny On Hematologic Malignancy Risk

 
• By Sue Sutter
Fireworks
Beti-cel administration led to transfusion independence for the majority of TDT patients in Phase III trials. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers